Biological immunotherapy effectively prevents renal cancer metastasis

Kidney cancer is the most common kidney tumor in adults. Metastasis often occurs in the late stage of kidney cancer. If metastasis occurs, it means that the disease has further deteriorated and treatment should be taken in time. Chemotherapy can be used first for kidney cancer metastasis. Chemotherapy can kill metastatic cancer cells and control the development of the disease. After that, DC-CIK biological therapy can be used to better alleviate chemotherapy reactions and help chemotherapy proceed smoothly.

DC-CIK biological immunotherapy is harmless and has no toxic side effects on patients with lung metastatic renal cancer. The DC, CIK cells and antigens used in the DC-CIK biological therapy are all taken from the patient's body and there will be no rejection reaction. At the same time, all operations are carried out in a GMP laboratory with overall Class 10,000 and local Class 100 clean standards. It is a very mature personalized cell therapy technology.

Biological immunotherapy is a treatment method that uses certain biotechnologies to cultivate DC immune cells and CIK tumor-killing cells in a high-standard laboratory, and then uses a unique double-culture and double-infusion method to dual-culture and dual-infusion DC and CIK cells. After combining them into one, they are infused back into the patient's body to directly kill cancer cells and rebuild the autologous immune system.

Surgery, radiotherapy and chemotherapy are conventional methods for treating kidney cancer. Although these three treatment methods are very effective, they have disadvantages. Biological immunotherapy technology is an emerging treatment method for kidney cancer with significant efficacy.